-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Treatment options for malignant pleural mesothelioma (MPM) are limited.
Treatment options for malignant pleural mesothelioma (MPM) are limited.
The Phase 2 KEYNOTE-158 study is an ongoing open-label, multi-cohort, single-arm Phase 2 trial that recruits 18-year-olds who are intolerant to standard treatment or who have progressed after treatment, and have EOCG performance status 0-1 Points, MPM patients with tumor samples that can be assessed for biomarkers.
Objective response rate
Objective response rateFrom February 9, 2016 to August 16, 2016, a total of 118 patients were enrolled in the MPM cohort and received at least one dose of pembrolizumab.
Ten patients (8%) achieved objective remission.
Objective duration of relief
Objective duration of relief6 of 77 MPM patients with PD-L1 positive (8%) achieved an objective response (median response lasted 17.
6 of 77 MPM patients with PD-L1 positive (8%) achieved an objective response (median response lasted 17.
OS and PFS
OS and PFSThe median overall survival time was 10.
The median overall survival is 10.
Adverse events
Adverse events82 (69%) patients had treatment-related adverse events, and 14 (12%) patients had serious adverse events that were considered treatment-related.
In summary, pembrolizumab exhibits sustained anti-tumor activity and controllable toxicity in patients with advanced MPM, regardless of whether PD-L1 is positive or negative .
Pembrolizumab exhibits sustained anti-tumor activity and controllable toxicity in patients with advanced MPM, regardless of whether PD-L1 is positive or negative
Original source:
Original source:Timothy A Yap, et al.
org/10.
1016/S2213-2600(20)30515-4" target="_blank" rel="noopener">Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
in this message
